Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones.

Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones.
复制标题

DOI:
10.1098/rsob.160157
复制
发表时间:
2016-09
期刊:
影响因子:
5.8
通讯作者:
Sanderson MR
Sanderson MR
中科院分区:
生物学2区
文献类型:
--
作者:
Laponogov I;Pan XS;Veselkov DA;Cirz RT;Wagman A;Moser HE;Fisher LM;Sanderson MR

文献摘要

参考文献

被引文献

相似文献

作为合成和研究新的氟喹诺酮类抗菌剂的生物学特性及其对肺炎链球菌拓扑异构酶IV的靶向的计划的一部分,我们已经解决了两个新的7,8-桥氟喹诺酮(具有有利于紧密结合的限制性C7基团旋转)与来自S.和一个18-碱基对DNA结合位点-E-位点-通过我们的DNA作图研究发现在拓扑异构酶IV存在下强烈结合药物(Leo等,2005 J. Biol. Chem. 280,14 252-14 263,doi:10.1074/jbc.M500156200)。尽管对氟喹诺酮类抗生素的耐药性程度远低于β-内酰胺类和一系列核糖体结合抗生素,但迫切需要增加这类成功的临床使用药物的多样性。新的7,8-桥连剂ACHN-245和ACHN-454的喹诺酮部分与克林沙星、左氧氟沙星、曲氟沙星和曲氟沙星的喹诺酮部分类似地结合,但环状支架提供了化学修饰的可能性,以在活性位点与其他拓扑异构酶残基产生相互作用。
As part of a programme of synthesizing and investigating the biological properties of new fluoroquinolone antibacterials and their targeting of topoisomerase IV from Streptococcus pneumoniae, we have solved the X-ray structure of the complexes of two new 7,8-bridged fluoroquinolones (with restricted C7 group rotation favouring tight binding) in complex with the topoisomerase IV from S. pneumoniae and an 18-base-pair DNA binding site—the E-site—found by our DNA mapping studies to bind drug strongly in the presence of topoisomerase IV (Leo et al. 2005 J. Biol. Chem. 280, 14 252–14 263, doi:10.1074/jbc.M500156200). Although the degree of antibiotic resistance towards fluoroquinolones is much lower than that of β-lactams and a range of ribosome-bound antibiotics, there is a pressing need to increase the diversity of members of this successful clinically used class of drugs. The quinolone moiety of the new 7,8-bridged agents ACHN-245 and ACHN-454 binds similarly to that of clinafloxocin, levofloxacin, moxifloxacin and trovofloxacin but the cyclic scaffold offers the possibility of chemical modification to produce interactions with other topoisomerase residues at the active site.
DOI: 10.1093/nar/gkt749
发表时间: 2013-11
影响因子: 14.9
作者:
Laponogov I;Veselkov DA;Crevel IM;Pan XS;Fisher LM;Sanderson MR
通讯作者: Sanderson MR
肺炎链球菌的断裂 - 重新结构域IV:革兰氏阳性喹诺酮靶标的晶体结构。
DOI: 10.1371/journal.pone.0000301
发表时间: 2007-03-21
期刊: PloS one
影响因子: 3.7
作者:
Laponogov I;Veselkov DA;Sohi MK;Pan XS;Achari A;Yang C;Ferrara JD;Fisher LM;Sanderson MR
通讯作者: Sanderson MR
DOI: 10.1371/journal.pone.0011338
发表时间: 2010-06-28
期刊: PloS one
影响因子: 3.7
作者:
Laponogov I;Pan XS;Veselkov DA;McAuley KE;Fisher LM;Sanderson MR
通讯作者: Sanderson MR
DOI: 10.1371/journal.pone.0003201
发表时间: 2008-09-12
期刊: PloS one
影响因子: 3.7
作者:
Sohi MK;Veselkov DA;Laponogov I;Pan XS;Fisher LM;Sanderson MR
通讯作者: Sanderson MR
抗菌QPT-1,抗癌药物依托泊苷和莫西沙星抑制DNA循环酶的结构基础。
DOI: 10.1038/ncomms10048
发表时间: 2015-12-07
影响因子: 16.6
作者:
Chan PF;Srikannathasan V;Huang J;Cui H;Fosberry AP;Gu M;Hann MM;Hibbs M;Homes P;Ingraham K;Pizzollo J;Shen C;Shillings AJ;Spitzfaden CE;Tanner R;Theobald AJ;Stavenger RA;Bax BD;Gwynn MN
通讯作者: Gwynn MN